Please login to the form below

Not currently logged in
Email:
Password:

Pfizer appoints chief scientific officer

Dr Ole Isacson will lead the neuroscience research unit

Pfizer Ole IsacsonPfizer has appointed Dr Ole Isacson as chief scientific officer and senior vice president of its neuroscience research unit, from 16 September.

Dr Isacson joins the pharma giant from Harvard Medical School, where he is a professor of neurology, and will continue to serve in an educational role while at Pfizer.

Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic neurology research centres.

Dr Isacson is a founding director of the Neuroregeneration Institute at McLean Hospital in the US, and currently serves as editor-in-chief of the Molecular and Cellular Neuroscience journal.

Previously, he has been a president of both the American Society for Neural Transplantation and Repair and the international Cell Transplantation Society.

Dr Mikael Dolsten, president of worldwide research and development at Pfizer, said: “Dr Isacson's deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer's and Parkinson's disease, where we are working to advance potential breakthrough therapies to fill the tremendous unmet need that exists for patients.

“In addition, his strong ties in the local academic community will be important as our Cambridge site continues to drive collaborations with leading scientific and academic institutions that can help us speed the pace of discovery.”

9th September 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Market Shaping for Better Healthcare Decisions
82% of healthcare business professionals agreed that it is important to get market shaping right to achieve future brand success....
launch engagement
Launch engagement
How the pandemic is forcing a fresh focus on the human touch and fresh thinking about engagement...
Everything you need to know about patient groups and clinical trials
Patient advocacy groups (PAGs) and pharma/biopharma/biotech and MedTech industries are all working towards the same goal: to improve health outcomes. And as PAGs are key stakeholders in the clinical trial...